Publications by authors named "Craig Portell"

Claim this Profile
B
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell Lymphoma.
Yucai Wang, Melissa C Larson, Steven R Hwang, Diego Villa, Laveniya Kugathasan, Craig A Portell

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relapsed Chronic Lymphocytic Leukemia Heralded by Parathyroid Hormone Related Peptide-Mediated Hypercalcemia.
Srikar Tallavajhala, Joanna Lee, Sean C Dougherty, Brett R Kurpiel, Craig A Portell

Clin Case Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance Rituximab Following Rituximab Induction for Follicular Lymphoma: A Single-Center Experience.
Lukas L Lauer, Craig A Portell

Clin Lymphoma Myeloma Leuk· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of the ECHELON-3 study: brentuximab vedotin combination treatment in people with diffuse large B-cell lymphoma.
Nancy L Bartlett, Uwe Hahn, Won-Seog Kim, Isabelle Fleury, Kamel Laribi, Craig A Portell

Future Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of venetoclax added to bendamustine and obinutuzumab in patients with high-risk follicular lymphoma as front-line therapy: PrE0403.
Craig A Portell, Opeyemi A Jegede, Nina Wagner-Johnston, Grzegorz S Nowakowski, Christopher Fletcher

Blood Cancer J· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.
Nancy L Bartlett, Uwe Hahn, Won-Seog Kim, Isabelle Fleury, Kamel Laribi, Craig A Portell

J Clin Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applications of the partial-order continual reassessment method in the early development of treatment combinations.
Nolan A Wages, Patrick M Dillon, Craig A Portell, Craig L Slingluff, Gina R Petroni

Clin Trials· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.
Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D Phelan, Da Wei Huang, Craig A Portell

N Engl J Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective study.
Alexandra Rezazadeh, Aniko Szabo, Arushi Khurana, David J Inwards, Matthew A Lunning, Craig A Portell

Haematologica· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7).
Simone Filosto, Saran Vardhanabhuti, Miguel A Canales, Xavier Poiré, Lazaros J Lekakis, Craig A Portell

Blood Cancer Discov· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central nervous system prophylaxis in diffuse large B-cell lymphoma: What does the evidence tell us?
Jeffrey Lantz, Craig A Portell, Emily C Ayers

Blood Rev· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma.
Yazeed Sawalha, Subir Goyal, Jeffrey M Switchenko, Jason T Romancik, Manali Kamdar, Craig A Portell

Blood Adv· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosis.
Kallesh D Jayappa, Brian Tran, Vicki L Gordon, Christopher Morris, Shekhar Saha, Craig A Portell

J Clin Invest· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In-depth cellular and humoral dynamics of the response to COVID-19 vaccine booster in patients with chronic B-cell neoplasms.
Emily Ayers, Glenda Canderan, Michael E Williams, Behnam Keshavarz, Craig A Portell

Blood Cancer J· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study.
Brian T Hess, Anshu Giri, Yeonhee Park, Krina K Patel, Brian K Link, Craig A Portell

Am J Hematol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma.
Matthew J Cortese, Wei Wei, Sebastian Cerdeña, Marcus P Watkins, Marissa Olson, Craig Portell

Leuk Lymphoma· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CNS prophylaxis in DLBCL: first do no harm.
Craig A Portell

Blood· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.
Craig A Portell, Nolan A Wages, Brad S Kahl, Lihua E Budde, Robert W Chen

Blood Adv· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
Victor Manuel Orellana-Noia, Daniel R Reed, Ashley Alesia McCook, Jeremy Michael Sen, Christian M Barlow, Craig A Portell

Blood· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
Stephen Opat, Alessandra Tedeschi, Kim Linton, Pamela McKay, Bei Hu, Craig A Portell

Clin Cancer Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies.
Lindsey E Roeker, Toby A Eyre, Meghan C Thompson, Nicole Lamanna, Alexander R Coltoff, Craig A Portell

Blood· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL.
Kallesh D Jayappa, Vicki L Gordon, Christopher G Morris, Briana Wilson, B Dharmaveer Shetty, Craig A Portell

Blood Adv· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma.
Victor M Orellana-Noia, Krista Isaac, Mary-Kate Malecek, Nancy L Bartlett, Timothy J Voorhees, Craig A Portell

Blood Adv· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management.
Krista M Isaac, Craig A Portell, Michael E Williams

Curr Oncol Rep· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.
Juan Pablo Alderuccio, Adam J Olszewski, Andrew M Evens, Graham P Collins, Alexey V Danilov, Craig A Portell

Blood Adv· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis